GLP-1 Receptor Agonist Use Not Linked to Increased Suicide Risk
MONDAY, March 3, 2025 -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors in adjusted analyses, according to a study published online Feb. 26 in The BMJ.
Samantha B. Shapiro, from the Jewish General Hospital in Montreal, and colleagues conducted an active comparator, new user cohort study to examine whether use of GLP-1 receptor agonists is associated with an increased risk for suicidal ideation, self-harm, and suicide compared with DPP-4 inhibitor or SGLT-2 inhibitor use. The first cohort included 36,082 GLP-1 receptor agonist users and 234,028 DPP-4 inhibitor users, and the second cohort included 32,336 GLP-1 receptor agonist users and 96,212 SGLT-2 inhibitor users.
In crude analyses, the researchers found an increased incidence of suicidality with GLP-1 receptor agonist versus DPP-4 inhibitor use (crude incidence rates, 3.9 versus 1.8 per 1,000 person-years; hazard ratio, 2.08; 95 percent confidence interval, 1.83 to 2.36). After accounting for confounding factors, this estimate decreased to a null value (hazard ratio, 1.02; 95 percent confidence interval, 0.85 to 1.23). GLP-1 receptor agonist use was also associated with an increased risk for suicidality compared with SGLT-2 inhibitor use (crude incidence rates, 4.3 versus 2.7 per 1,000 person-years; hazard ratio, 1.60; 95 percent confidence interval, 1.37 to 1.87), but the correlation did not persist after accounting for confounding factors (hazard ratio, 0.91; 95 percent confidence interval, 0.73 to 1.12). When suicidal ideation, self-harm, and suicide were analyzed separately in both cohorts, the findings were similar.
"These findings should provide some reassurance with respect to the psychiatric safety of these drugs," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Higher Tattoo Exposure Linked to Reduced Melanoma Risk
MONDAY, Sept. 29, 2025 -- Higher tattoo exposure may be associated with reduced melanoma risk, according to a study published online Aug. 21 in the Journal of the National Cancer...
Antithymocyte Globulin Cuts Loss of β-Cell Function in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes, according to a...
Loss of Therapeutic Benefit Seen After Stopping Baricitinib in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D), according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.